ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CBDS Cannabis Sativa Inc (QB)

0.028
0.0091 (48.15%)
26 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cannabis Sativa Inc (QB) USOTC:CBDS OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0091 48.15% 0.028 0.0239 0.029 0.028 0.0185 0.0185 10,307,591 21:59:00

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

21/08/2023 5:03pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

___________________

 

FORM 10-Q

___________________

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2023

 

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _____________ to _____________

 

Commission File Number: 000-53571

 

Cannabis Sativa, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

20-1898270

(State or Other Jurisdiction

 

(I.R.S. Employer

of Incorporation)

 

Identification No.)

 

450 Hillside Dr. #A224, Mesquite, Nevada 89027

(Address of Principal Executive Office) (Zip Code)

 

(702) 762-3123

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address, and former fiscal year, if changed since last report)

———————

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered.

None

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated Filer

Smaller reporting company

Emerging growth company

 

 

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☒ No

 

The number of shares of the issuer’s Common Stock outstanding as of August 18, 2023, is 50,048,273

 

 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Attached after signature page.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Certain statements in this Report constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms, and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

 

Results of Operations

 

Three Months Ended June 30, 2023, compared with the Three Months Ended June 30, 2022

 

 

 

Three Months Ended

 

 

 

A

 

 

B

 

 

A-B

 

 

 

June 30,

2023

 

 

June 30,

2022

 

 

Change

 

 

Change %

 

REVENUE

 

$323,197

 

 

$456,088

 

 

$(132,891 )

 

 

(29 )%

Cost of revenues

 

 

120,608

 

 

 

170,541

 

 

 

(49,933 )

 

 

(29 )%

Cost of sales % of total sales

 

 

37%

 

 

37%

 

 

 

 

 

(-0-)

%

Gross profit

 

 

202,589

 

 

 

285,547

 

 

 

(82,958 )

 

 

(29 )%

Gross profit % of sales

 

 

63%

 

 

63%

 

 

 

 

 

(-0-)

 %

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

 

108,757

 

 

 

89,502

 

 

 

19,255

 

 

 

22%

Depreciation and amortization

 

 

37,990

 

 

 

42,354

 

 

 

(4,364 )

 

 

(10 )%

Wages and salaries

 

 

209,690

 

 

 

184,150

 

 

 

25,540

 

 

 

14%

Advertising

 

 

4,630

 

 

 

15,308

 

 

 

(10,678 )

 

 

(70 )%

General and administrative

 

 

146,339

 

 

 

128,762

 

 

 

17,577

 

 

 

14%

Total expenses

 

 

507,406

 

 

 

460,076

 

 

 

47,330

 

 

 

10%

NET LOSS FROM CONTINUING OPERATIONS

 

 

(304,817 )

 

 

(174,529 )

 

 

(130,288)

 

 

(75 )%

 

Revenue for the three months ended June 30, 2023, decreased 29% compared to the three months ended June 30, 2022. Cost of revenues as a percentage of sales decreased 29% between the periods. The decrease in revenues is primarily a result of the lessening impact COVID-19 as we progressed into 2022.  In 2021, COVID-19 and the associated concerns with in-person visits to doctors’ offices caused a surge in the use of telemedicine in general and the Company benefitted from this with an increase in customers seeking medical marijuana cards through telemedicine.  The first quarter of 2022 continued to benefit somewhat from this surge but as the public grew more accustomed to the pandemic, and as vaccinations and booster shots became widely available, the demand for remote visits with physicians for medical marijuana cards decreased. This softening in the demand for our service continued during the second quarter of 2023.

 

 
2

 

 

Total operating expenses increased 10% in the three months ended June 30, 2023 compared with the three months ended June 30, 2022.  Professional fees, wages and salaries and general and administrated fees increased. Wages and salaries decreased as a result of the death of our CFO in the fourth quarter of 2022 and our CEO assuming those duties without an increase in salary, however $88,200 was paid out in bonuses.  Professional fees and general and administrative expenses also increased as audit expenses and other general expenses went up for additional time and rate increases.

 

Six Months Ended June 30, 2023, compared with the Six Months Ended June 30, 2022

 

 

 

Six Months Ended

 

 

 

A

 

 

B

 

 

A-B

 

 

 

June 30,

2023

 

 

June 30,

2022

 

 

Change

 

 

Change %

 

REVENUE

 

$668,565

 

 

$879,789

 

 

$(211,224 )

 

 

(24 )%

Cost of revenues

 

 

226,009

 

 

 

329,230

 

 

 

(103,221 )

 

 

(31 )%

Cost of sales % of total sales

 

 

34%

 

 

37%

 

 

 

 

 

 

(3 )%

Gross profit

 

 

442,556

 

 

 

550,559

 

 

 

(108,003 )

 

 

(20 )%

Gross profit % of sales

 

 

66%

 

 

63%

 

 

 

 

 

 

3%

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

 

161,898

 

 

 

211,408

 

 

 

(49,510

)

 

 

(23)%

Depreciation and amortization

 

 

75,979

 

 

 

84,707

 

 

 

(8,728 )

 

 

(10 )%

Wages and salaries

 

 

324,793

 

 

 

370,911

 

 

 

(46,118

 

 

(12)%

Advertising

 

 

7,476

 

 

 

31,529

 

 

 

(24,053 )

 

 

(76 )%

General and administrative

 

 

289,588

 

 

 

356,364

 

 

 

(66,776

 

 

(19)%

Total expenses

 

 

859,734

 

 

 

1,054,919

 

 

 

(195,185

 

 

(19)%

NET LOSS FROM CONTINUING OPERATIONS

 

 

(417,178 )

 

 

(504,360 )

 

 

87,182

 

 

17 %

 

Revenue for the six months ended June 30, 2023, decreased 24% compared to the six months ended June 30, 2022. Cost of revenues as a percentage of sales decreased 31% between the periods. The decrease in revenues is primarily a result of the lessening impact COVID-19 as we progressed into 2022.  In 2021, COVID-19 and the associated concerns with in-person visits to doctors’ offices caused a surge in the use of telemedicine in general and the Company benefitted from this with an increase in customers seeking medical marijuana cards through telemedicine.  The first quarter of 2022 continued to benefit somewhat from this surge but as the public grew more accustomed to the pandemic, and as vaccinations and booster shots became widely available, the demand for remote visits with physicians for medical marijuana cards decreased. This softening in the demand for our service continued during the second quarter of 2023.

 

Total operating expenses decreased 19% in the six months ended June 30, 2023 compared with the six months ended June 30, 2022.  Professional fees, wages and salaries and general and administrated fees decreased. Wages and salaries decreased as a result of the death of our CFO in the fourth quarter of 2022 and our CEO assuming those duties without an increase in salary, however $88,200 was paid out in bonuses. 

 

Liquidity and Capital Resources

 

Cash used in operating activities was $51,857 and $40,886 in the six months period ended June 30, 2023 and 2022, respectively. In the six months period ended June 30, 2023, financing activities provided $22,884, consisting of net proceeds from related party notes. We ended the second quarter of 2023 with $58,124 in cash on hand.

 

 
3

 

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $816,437 and $418,889, respectively, for the six months ended June 30, 2023, and 2022 and had an accumulated deficit of $81,458,477 as of June 30, 2023. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.

 

The amount of cash on hand the Company has does not provide sufficient liquidity to meet the immediate needs of our current operations.

 

Off Balance Sheet Arrangements

 

None

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Conclusions of Management Regarding Effectiveness of Disclosure Controls and Procedures

 

At the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operations of the Company’s disclosure controls and procedures (as defined in Rule 13a – 15(e) and Rule 15d – 15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective as it was determined that there were material weaknesses affecting our disclosure controls and procedures.

 

Management of the Company believes that these material weaknesses are due to the small size of the company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting during the quarter ended June 30, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 
4

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not a party to any material legal proceedings, and, to the best of our knowledge, no such legal proceedings have been threatened against us.

 

Item 1A. Risk Factors

 

Not required.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the fiscal quarter ended June 30, 2023, 2,031,910 shares of common stock were issued to convert $54,000 of a note payable to a non-related party. Also, during the quarter, the Company issued a convertible note to a contract services provider in the principal amount of $72,262. The note bears interest at 8% and is due December 31, 2023.

 

The securities issued were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

 
5

 

 

Item 6. Exhibits.

 

The following documents are included as exhibits to this report:

 

(a) Exhibits

 

Exhibit

Number

 

SEC

Reference

Number

 

Title of Document

 

Notes

 

 

 

 

 

 

 

3.1

 

3

 

Articles of Incorporation

 

(1)

3.2

 

3

 

Bylaws

 

(1)

31.1

 

31

 

Section 302 Certification of Principal Executive Officer

 

 

31.2

 

31

 

Section 302 Certification of Principal Financial Officer

 

 

32.1

 

32

 

Section 1350 Certification of Principal Executive Officer

 

 

32.2

 

32

 

Section 1350 Certification of Principal Financial Officer

 

 

101.INS

 

 

 

XBRL Instance Document

 

(2)

101.SCH

 

 

 

XBRL Taxonomy Extension Schema

 

(2)

101.CAL

 

 

 

XBRL Taxonomy Extension Calculation Linkbase

 

(2)

101.DEF

 

 

 

XBRL Taxonomy Extension Definition Linkbase

 

(2)

101.LAB

 

 

 

XBRL Taxonomy Extension Label Linkbase

 

(2)

101.PRE

 

 

 

XBRL Taxonomy Extension Presentation Linkbase

 

(2)

 

(1) Incorporated by reference to Exhibits 3.01 and 3.02 of the Company’s Registration Statement on Form 10 filed January 28, 2009.

(2) XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.  

 

 
6

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Cannabis Sativa, Inc.

 

Date: August 18, 2023

 

By:  

/s/ David Tobias

 

 

David Tobias

Principal Executive Officer

Principal Financial Officer

 

 

 

7

 

 

CANNABIS SATIVA, INC.

 

Contents

 

Page

 

FINANCIAL STATEMENTS - UNAUDITED – for the three and six months ended June 30, 2023 and 2022:

 

 

 

 

Condensed Consolidated balance sheets

 

FS - 2

 

 

 

 

 

Condensed Consolidated statements of operations

 

FS - 3

 

 

 

 

 

Condensed Consolidated statements of changes in stockholders’ equity

 

FS - 4

 

 

 

 

 

Condensed Consolidated statements of cash flows

 

FS - 5

 

 

 

 

 

Notes to Condensed consolidated financial statements

 

FS – 6 through FS – 13

 

 

 
FS-1

Table of Contents

 

CANNABIS SATIVA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED

 

 

  

 

 

June 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash

 

$58,124

 

 

$97,445

 

Investment in equity securities, at fair value

 

 

1,200

 

 

 

379,858

 

Right of use asset

 

 

24,958

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

 

84,282

 

 

 

477,303

 

 

 

 

 

 

 

 

 

 

Advances to related party

 

 

75,054

 

 

 

55,666

 

Right of use asset

 

 

 

 

 

38,968

 

Property and equipment, net

 

 

2,572

 

 

 

2,709

 

Intangible assets, net

 

 

83,101

 

 

 

158,943

 

Goodwill

 

 

1,837,202

 

 

 

1,837,202

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$2,082,211

 

 

$2,570,791

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$133,093

 

 

$164,411

 

Operating lease liability, current

 

 

24,958

 

 

 

28,736

 

Accrued interest - related parties

 

 

16,474

 

 

 

16,374

 

Convertible notes payable

 

 

211,762

 

 

 

168,500

 

Notes payable to related parties

 

 

144,421

 

 

 

91,700

 

 

 

 

 

 

 

 

 

 

Total Current Liabilities

 

 

530,708

 

 

 

469,721

 

 

 

 

 

 

 

 

 

 

Long-term liabilities

 

 

 

 

 

 

 

 

Operating lease liability, long term

 

 

 

 

 

10,232

 

Stock payable

 

 

542,421

 

 

 

418,156

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

1,073,129

 

 

 

898,109

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Notes 6 and 8)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock $0.001 par value; 5,000,000 shares authorized; -0- and 777,654 issued and outstanding, respectively

 

 

 

 

 

 

Common stock $0.001 par value; 495,000,000 shares authorized; 50,048,273 and 45,566,363 shares issued and outstanding, respectively

 

 

50,049

 

 

 

45,567

 

Additional paid-in capital

 

 

81,087,973

 

 

 

80,939,618

 

Accumulated deficit

 

 

(81,458,477)

 

 

(80,603,069)

 

 

 

 

 

 

 

 

 

Total Cannabis Sativa, Inc. Stockholders’ Equity (Deficit)

 

 

(320,455)

 

 

382,116

 

 

 

 

 

 

 

 

 

 

Non-Controlling Interest

 

 

1,329,537

 

 

 

1,290,566

 

 

 

 

 

 

 

 

 

 

Total Stockholders’ Equity

 

 

1,009,082

 

 

 

1,672,682

 

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders’ Equity

 

$2,082,211

 

 

$2,570,791

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 
FS-2

Table of Contents

 

CANNABIS SATIVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

 

 

 

 

   

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

June 30,

 

 

June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$323,197

 

 

$456,088

 

 

$668,565

 

 

$879,789

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenues

 

 

120,608

 

 

 

170,541

 

 

 

226,009

 

 

 

329,230

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

202,589

 

 

 

285,547

 

 

 

442,556

 

 

 

550,559

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

 

108,757

 

 

 

89,502

 

 

 

161,898

 

 

 

211,408

 

Depreciation and amortization

 

 

37,990

 

 

 

42,354

 

 

 

75,979

 

 

 

84,707

 

Wages and salaries

 

 

209,690

 

 

 

184,150

 

 

 

324,793

 

 

 

370,911

 

Advertising

 

 

4,630

 

 

 

15,308

 

 

 

7,476

 

 

 

31,529

 

General and administrative

 

 

146,339

 

 

 

128,762

 

 

 

289,588

 

 

 

356,364

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Operating Expenses

 

 

507,406

 

 

 

460,076

 

 

 

859,734

 

 

 

1,054,919

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(304,817)

 

 

(174,529)

 

 

(417,178)

 

 

(504,360)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (Income) and Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (gain) loss on investment

 

 

2,400

 

 

 

142,012

 

 

 

213,883

 

 

 

(104,642)

Loss on debt settlement

 

 

(114)

 

 

 

 

 

10,527

 

 

 

 

Loss on sale of investment securities

 

 

 

 

 

 

 

 

155,735

 

 

 

 

Interest expense

 

 

9,233

 

 

 

1,995

 

 

 

19,114

 

 

 

19,171

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other (Income) Expenses, Net

 

 

11,519

 

 

 

144,007

 

 

 

399,259

 

 

 

(85,471)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Income Taxes

 

 

(316,336)

 

 

(318,536)

 

 

(816,437)

 

 

(418,889)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income Taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss for the Period

 

 

(316,336)

 

 

(318,536)

 

 

(816,437)

 

 

(418,889)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income attributable to non-controlling interest - PrestoCorp

 

 

16,150

 

 

 

32,029

 

 

 

38,971

 

 

 

22,567

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss for the Period Attributable To Cannabis Sativa, Inc.

 

$(332,486)

 

$(350,565)

 

$(855,408)

 

$(441,456)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss for the Period per Common Share: Basic & Diluted

 

$(0.01)

 

$(0.01)

 

$(0.02)

 

$(0.01)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic & Diluted

 

 

48,169,783

 

 

 

31,394,764

 

 

 

46,926,618

 

 

 

31,370,814

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 
FS-3

Table of Contents

 

CANNABIS SATIVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022 - UNAUDITED

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

Non-controlling

 

 

 

 

 

Preferred Stock

 

 

Common Stock

 

 

 Paid-In

 

 

Accumulated

 

 

Interest -

 

 

 

 

 

 Shares

 

 

 Amount

 

 

 Shares

 

 

 Amount

 

 

Capital

 

 

 Deficit

 

 

 Prestocorp

 

 

Total 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - January 1, 2022

 

 

777,654

 

 

$778

 

 

 

30,746,865

 

 

$30,748

 

 

$79,151,240

 

 

$(79,475,968)

 

$1,338,102

 

 

$1,044,900

 

Net loss for period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(90,891)

 

 

(9,462)

 

 

(100,353)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - March 31, 2022

 

 

777,654

 

 

 

778

 

 

 

30,746,865

 

 

 

30,748

 

 

 

79,151,240

 

 

 

(79,566,859)

 

 

1,328,640

 

 

 

944,547

 

Conversion of preferred to common (1:1)

 

 

(131,880)

 

 

(132)

 

 

131,880

 

 

 

132

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of preferred to common (19:1)

 

 

(288,223)

 

 

(288)

 

 

5,476,237

 

 

 

5,476

 

 

 

(5,188)

 

 

 

 

 

 

 

 

 

Shares issued for services

 

 

458,333

 

 

 

458

 

 

 

1,306,242

 

 

 

1,306

 

 

 

348,743

 

 

 

 

 

 

 

 

 

350,507

 

Shares issued in consideration of notes and interest payable - related parties

 

 

 

 

 

 

 

 

7,089,255

 

 

 

7,089

 

 

 

1,410,762

 

 

 

 

 

 

 

 

 

1,417,851

 

Net income (loss) for period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(350,565)

 

 

32,029

 

 

 

(318,536)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - June 30, 2022

 

 

815,884

 

 

$816

 

 

 

44,750,479

 

 

$44,751

 

 

$80,905,557

 

 

$(79,917,424)

 

$1,360,669

 

 

$2,394,369

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - January 1, 2023

 

 

 

 

$

 

 

 

45,566,363

 

 

$45,567

 

 

$80,939,618

 

 

$(80,603,069)

 

$1,290,566

 

 

$1,672,682

 

Common Stock Issued - Note Payable Conversion

 

 

 

 

 

 

 

 

320,513

 

 

 

321

 

 

 

25,316

 

 

 

 

 

 

 

 

 

25,637

 

Net income (loss) for the period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(522,922)

 

 

22,821

 

 

 

(500,101)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - March 31, 2023

 

 

 

 

 

 

 

 

45,886,876

 

 

 

45,888

 

 

 

80,964,934

 

 

 

(81,125,991)

 

 

1,313,387

 

 

 

1,198,218

 

Common Stock Issued - Note Payable Conversion

 

 

 

 

 

 

 

 

1,711,397

 

 

 

1,711

 

 

 

37,289

 

 

 

 

 

 

 

 

 

39,000

 

Shares issued for services

 

 

 

 

 

 

 

 

2,450,000

 

 

 

2,450

 

 

 

85,750

 

 

 

 

 

 

 

 

 

88,200

 

Net income (loss) for the period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(332,486)

 

 

16,150

 

 

 

(316,336)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - June 30, 2023

 

 

 

 

$

 

 

 

50,048,273

 

 

$50,049

 

 

$81,087,973

 

 

$(81,458,477)

 

$1,329,537

 

 

$1,009,082

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

  

 
FS-4

Table of Contents

 

CANNABIS SATIVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED

 

 

 

   

For the six months ended June 30,

 

2023

 

 

2022

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss for the period

 

$(816,437)

 

$(418,889)

Adjustments to reconcile net loss for the period to net cash used in operating activities:

 

 

 

 

 

 

 

 

Unrealized loss (gain) on investments

 

 

213,883

 

 

 

(104,642)

Depreciation and amortization

 

 

75,979

 

 

 

84,707

 

Loss on debt settlement

 

 

10,527

 

 

 

 

Loss on sale of investment securities

 

 

155,735

 

 

 

 

Stock issued for services

 

 

88,200

 

 

 

350,507

 

Stock payable for services

 

 

196,527

 

 

 

 

Note payable issued for services

 

 

55,000

 

 

 

30,000

 

Write off of abandoned equipment

 

 

 

 

 

583

 

Changes in Assets and Liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

 

(31,321)

 

 

1,424

 

Accrued interest - related parties

 

 

50

 

 

 

15,424

 

Net Cash Provided by (Used in) Operating Activities

 

 

(51,857)

 

 

(40,886)

 

 

 

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Proceeds from sale of stock held for investment

 

 

9,040

 

 

 

 

Advances to related party

 

 

(19,388)

 

 

 

Net Cash Used in Investing Activities

 

 

(10,348)

 

 

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Proceeds from related parties notes payable, net

 

 

22,884

 

 

 

41,340

 

Net Cash Provided by Financing Activities

 

 

22,884

 

 

 

41,340

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH

 

 

(39,321)

 

 

454

 

 

 

 

 

 

 

 

 

 

CASH AT BEGINNING OF PERIOD

 

 

97,445

 

 

 

194,060

 

 

 

 

 

 

 

 

 

 

CASH AT END OF PERIOD

 

$58,124

 

 

$194,514

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosures of Non Cash Activities:

 

 

 

 

 

 

 

 

Noncash investing and financing activities

 

 

 

 

 

 

 

 

Shares issued in consideration of notes and interest payable - related parties

 

$30,000

 

 

$1,417,851

 

     Shares issued in consideration of convertible notes payable

 

$

 39,000

 

 

 

 

 

Recognition of operating lease liability and right of use asset

 

$

 

 

$56,595

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  

 
FS-5

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2023 and 2022

 

1. Organization and Summary of Significant Accounting Policies

 

Nature of Business:

 

Cannabis Sativa, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including:

 

 

·

PrestoCorp, Inc. (“PrestoCorp”)

 

·

Wild Earth Naturals, Inc. (“Wild Earth”)

 

·

Kubby Patent and Licenses Limited Liability Company (“KPAL”)

 

·

Hi Brands, International, Inc. (“Hi Brands”)

 

·

Eden Holdings LLC (“Eden”).

 

PrestoCorp is a 51% owned subsidiary and until April 22, 2021, GKMP and iBud were 51% and 50.1% owned subsidiaries. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At December 31, 2022 and 2021, PrestoCorp is the sole operating subsidiary. Until sale of the Company’s interest in April 2021, GKMP and iBud tender were operating subsidiaries although iBud was not generating any revenue.

 

Our primary operations for the years ended December 31, 2022 through June 30, 2023 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.

 

Basis of Presentation

 

Operating results for the three and six months ended June 30, 2023 may not be indicative of the results expected for the full year ending December 31, 2023. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2022, as filed with the United States Securities and Exchange Commission on April 20, 2023.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023, and its results of operations, cash flows, and changes in stockholders’ equity for the three and six months ended June 30, 2023. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.

 

Principles of Consolidation:

 

The consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.

 

 
FS-6

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2023 and 2022

 

Going Concern:

 

The Company has an accumulated deficit of $81,458,477 at June 30, 2023, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

 

Use of Estimates:

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

 

 Net Loss per Share:

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the six months ended June 30, 2023 and 2022, the Company had 50,000 and 175,000 outstanding warrants, respectively, and -0- and 777,654 shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted. The number of shares that can be converted per the convertible note agreement can be converted after December 31, 2022 thus are dilutive as of June 30, 2023.

 

Recent Accounting Pronouncement:

 

Accounting Standards Updates Adopted

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

 

 
FS-7

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2023 and 2022

 

2. Intangibles and Goodwill

 

The Company considers all intangibles to be definite-lived assets with lives of 5 to 10 years. Intangibles consisted of the following at June 30, 2023   and December 31, 2022:

 

 

 

June 30,

2023

 

 

December 31,

2022

 

CBDS.com website (Cannabis Sativa)

 

$13,999

 

 

$13,999

 

Intellectual Property Rights (PrestoCorp)

 

 

240,000

 

 

 

240,000

 

Patents and Trademarks (KPAL)

 

 

1,281,411

 

 

 

1,281,411

 

Total Intangibles

 

 

1,535,410

 

 

 

1,535,410

 

Less: Accumulated Amortization

 

 

(1,452,309 )

 

 

(1,376,467 )

Net Intangible Assets

 

$83,101

 

 

$158,943

 

 

Amortization expense for the three and six months ended June 30, 2023 and 2022 was $37,921 (2022: $42,285) and $75,842 (2022: $84,570), respectively.

 

Amortization of intangibles through 2027 is: 

 

July 1, 2023 to June 30, 2024

 

$78,432

 

July 1, 2024 to June 30, 2025

 

 

932

 

July 1, 2025 to June 30, 2026

 

 

932

 

July 1, 2026 to June 30, 2027

 

 

932

 

July 1, 2027 to June 30, 2028

 

 

932

 

July 1, 2028 to June 30, 2029

 

 

941

 

 

Goodwill in the amount of $3,010,202 was recorded as part of the acquisition of PrestoCorp that occurred on August 1, 2017. Cumulative impairment of the PrestoCorp goodwill totals $1,173,000 as of June 30, 2023 and December 31, 2022. The balance of goodwill at June 30, 2023 and December 31, 2022 was $1,837,202.

 

 
FS-8

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the  Six Months Ended June 30, 2023 and 2022

 

3. Related Party Transactions

 

In addition to items disclosed in Note 6, the Company had additional related party transactions during the six months ended June 30, 2023 and 2022.

 

Historically, the Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company’s outstanding shares.

 

During the six months ended June 30, 2023, David Tobias, the Company’s chief executive officer and director, loaned $22,721 to the Company for notes payable bearing interest at the rate of 5% per annum due on December 31, 2023. 

 

During the six months ended June 30, 2023, the Company and Cathy Carroll, director, entered into a note payable for $30,000 for compensation due her for services. Ms. Carroll’s note bears interest at 8% per annum and is due December 31, 2024. The note payable totaled $55,000 at December 31, 2022.

 

During the years ended December 31, 2022 and 2021, the Company recorded interest expense related to notes payable to related parties at the rates between 5% and 8% per annum in the amounts of $16,374 and $66,872, respectively.

 

The following tables reflect the related party note payable balances. 

 

 

 

Related party notes

 

 

Accrued interest

 

 

Total

 

 

 

June 30, 2023

 

David Tobias, CEO & Director

 

$55,421

 

 

$12,482

 

 

$67,903

 

New Compendium, greater than 10% Shareholder

 

 

-

 

 

 

1,906

 

 

 

1,906

 

Cathy Carroll, Director

 

 

85,000

 

 

 

986

 

 

 

85,986

 

Other Affiliates

 

 

4,000

 

 

 

1,100

 

 

 

5,100

 

Totals

 

$144,421

 

 

$16,474

 

 

$160,895

 

 

 

 

Related party notes

 

 

Accrued interest

 

 

Total

 

 

 

December 31, 2022

 

David Tobias, CEO & Director

 

$32,700

 

 

$12,482

 

 

$45,182

 

New Compendium, greater than 10% Shareholder

 

––

 

 

 

1,906

 

 

 

1,906

 

Cathy Carroll, Director

 

 

55,000

 

 

 

986

 

 

 

55,986

 

Other Affiliates

 

 

4,000

 

 

 

1,000

 

 

 

5,000

 

Totals

 

$91,700

 

 

$16,374

 

 

$108,074

 

 

During the three and six months ended June 30, 2023 and 2022, the Company incurred approximately $-0- (2022: $12,500) and $-0- (2022: $26,389), respectively, for consulting services from a nephew of the Company’s president. The services were accrued at June 30, 2022 and paid in common stock. These amounts are included in the statements of operations in general and administrative expenses.

 

 
FS-9

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the  Six Months Ended June 30, 2023 and 2022

 

At June 30, 2023 and December 31, 2022, the Company has a balance due from MJ Harvest, Inc., with whom the Company plans to merge, of $75,054 and $55,666 (see Note 8). The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to MJ Harvest, Inc. to cover operating expenses.

 

At June 30, 2023 and December 31, 2022 the Company had stock payable in the amount $542,421 and $345,893 due to related parties; directors and contract officers.

 

4. Investments

 

At June 30, 2023 and December 31, 2022, the Company owns -0- and 8,238,769 shares respectively, of common stock of Medical Cannabis Payment Solutions (ticker: REFG). At June 30, 2023 and December 31, 2022, the fair value of the investment in REFG was $-0- and $12,358, respectively. The Company sold all of its position in REFG during the six months ended June 30, 2023 and recognized a loss on the sale of investment securities in the amount of $155,735

 

In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG.

 

The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at June 30, 2023 and December 31, 2022 was $1,200 and $367,500 resulting in a gain (loss) of ($2,400) (2022: $114,000) and ($366,300) (2022: ($117,000)) for the change in fair value during the three and six months ended June 30, 2023 and 2022, respectively.

 

5. Convertible Notes Payable

 

On August 25, 2022 and November 7, 2022, the Company entered into an agreement with 1800 Diagonal Lending, LLC (“Diagonal”) whereby the Company issued convertible notes to Diagonal with principal amounts of $104,250 and $64,250, respectively. The notes bear interest at 10% and have terms of one year when payment of principal and interest is due. After 180 days, the notes are convertible into shares of the Company’s common stock the number of which determined by dividing the principal balance outstanding by 65% of the lowest trading price of the Company’s stock during the five previous trading days before the date of the conversion.  During the six months ended June 30, 2023, Diagonal converted $54,000 of their note payable from August into 2,031,910 shares of common stock.  As of June 30, 2023 amounts due to Diagonal total $50,250 and $64,250, respectively.

 

On January 1, 2023, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $72,262.  As stated in the January 1, 2023 agreement Ms. Merrill’s contract compensation will also be added to the note for her services through June 30, 2023 in the amount of $25,000. Total note payable at June 30, 2023 is $97,262.  The note bears interest at 8% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 20% discount.  Both methods are calculated using the lowest 3 closing prices during the 15 trading days preceding the first day of the next calendar quarter.

 

 
FS-10

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2023 and 2022

 

At June 30, 2023 and December 31, 2022, accrued interest payable and interest expense on these notes was $16,362 and $4,546. Accrued interest payable is included in accounts payable and accrued expenses on the consolidated balance sheet.

 

6. Stockholders’ Equity

 

Change in Authorized Shares

 

The Company increased the number of authorized common shares the Company is authorized to issue to 495,000,000 on August 8, 2022. This change in capital structure was approved without a meeting by the consent of the shareholders holding a majority of the common stock outstanding and Articles of Amendment were filed with the State of Nevada.

 

Securities Issuances

 

During the six months ended June 30, 2023, 2,031,910 shares of common stock were issued to convert $54,000 of a note payable to a non-related party.  See Note 5.

 

During the six months ended June 30, 2023, 2,450,000 shares of common stock were issued to pay bonuses in the amount of  $88,200

 

Stock payable at June 30, 2023 consists of 1,219,513 preferred shares and 838,415 common shares owed to members of the board of directors for directors’ fees and contract services. These shares were valued at $84,375 based on the fair value of the Company’s common stock at the date of board authorization. Subsequent to year end, no issuances of the shares have been made.

 

Stock payable at June 30, 2023 and December 31, 2022 consists of 5,025,814 and 1,306,302 preferred shares and 1,934,530 and 1,469,590 common shares, respectively, owed to members of the board of directors for directors’ fees and contract services. These shares were valued at $325,000 and  $212,500, respectively, based on the fair value of the Company’s common stock at the date of board authorization. An additional 5,874,988 and 2,393,873 common shares were owed to various non-related vendors at June 30, 2023 and December 31, 2022 valued at $217,421 and $205,656, respectively, based on the fair value of the Company’s common stock at the date of board authorization. Subsequent to year end, no issuances of the shares have been made.

 

Stock Compensation Plans

 

2020 Stock Plan

 

On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021. At June 30, 2023, 44,425 shares were available for future issuance.

 

 
FS-11

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2023 and 2022

 

Warrants

 

At June 30, 2023 and December 31, 2022, the Company has outstanding warrants to purchase 50,000 shares of the Company’s common stock. As of June 30, 2023, the warrants have an exercise price of $2.00 and expire in July and August 2023. During the six months ended June 30, 2023 and 2022, warrants activity consisted of the following: warrants issued – none (2022: none), warrants exercised – none (2022: none), warrants expired – none (2022: none).

 

7. Commitments and Contingencies

 

Leases.

 

PrestoCorp leased office space through WeWork in New York on a month-to-month basis which ended in April 2022. On April 12, 2022, PrestoCorp signed a new lease in New York with Spaces for a two-year term at $2,590 per month expiring in April 2024. Upon signing the lease with Spaces, the Company recognized a lease liability and a right of use asset of $56,595 using a discount rate of 10%. The future lease payments under the new lease are as follows:

 

From July 1, 2023 to June 30, 2024

 

$25,900

 

Less imputed interest

 

 

(942 )

Net lease liability

 

 

24,958

 

Current Portion

 

 

(24,958 )

Long-term portion

 

$

-0-

 

 

Rent expense for the three and six months ended June 30, 2023 and 2022 was $9,163 (2022: $2,602) and $17,579 (2022: $21,325), respectively.

 

Litigation.

 

In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of June 30, 2023, no claims are outstanding.

 

 
FS-12

Table of Contents

 

CANNABIS SATIVA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2023 and 2022

 

8. Proposed Merger with MJ Harvest, Inc.

 

On August 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with MJ Harvest, Inc. (“MJHI”). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger. The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the second quarter of calendar year 2023. The terms of the Merger Agreement are summarized below:

 

 

·

The name of the surviving company in the Merger will be Cannabis Sativa, Inc.

 

·

Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock.

 

·

The Merger is subject to majority approval of the shareholders of both MJHI and CBDS.

 

·

The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares.

 

·

The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Randy Lanier, Clinton Pyatt, and David Tobias.

 

·

The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer, Clinton Pyatt - Chief Operating Officer.

 

·

The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature.

 

·

No brokerage fees are payable in connection with the Merger.

 

·

If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated.

 

·

All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs.

 

9.  Subsequent Event

 

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

 

 
FS-13

 

nullnullnullnullv3.23.2
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 18, 2023
Cover [Abstract]    
Entity Registrant Name Cannabis Sativa, Inc.  
Entity Central Index Key 0001360442  
Document Type 10-Q  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company true  
Entity Current Reporting Status Yes  
Document Period End Date Jun. 30, 2023  
Entity Filer Category Non-accelerated Filer  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Entity Ex Transition Period false  
Entity Common Stock Shares Outstanding   50,048,273
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-53571  
Entity Incorporation State Country Code NV  
Entity Tax Identification Number 20-1898270  
Entity Interactive Data Current Yes  
Entity Address Address Line 1 450 Hillside  
Entity Address Address Line 2 Dr. #A224  
Entity Address City Or Town Mesquite  
Entity Address State Or Province NV  
Entity Address Postal Zip Code 89027  
City Area Code 702  
Local Phone Number 762-3123  
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current Assets    
Cash $ 58,124 $ 97,445
Investment in equity securities, at fair value 1,200 379,858
Right of use asset 24,958 0
Total Current Assets 84,282 477,303
Advances to related party 75,054 55,666
Right of use asset 0 38,968
Property and equipment, net 2,572 2,709
Intangible assets, net 83,101 158,943
Goodwill 1,837,202 1,837,202
Total Assets 2,082,211 2,570,791
Current Liabilities    
Accounts payable and accrued expenses 133,093 164,411
Operating lease liability, current 24,958 28,736
Accrued interest - related parties 16,474 16,374
Convertible notes payable 211,762 168,500
Notes payable to related parties 144,421 91,700
Total Current Liabilities 530,708 469,721
Long-term liabilities    
Operating lease liability, long term 0 10,232
Stock payable 542,421 418,156
Total Liabilities 1,073,129 898,109
Stockholders' Equity:    
Preferred stock $0.001 par value; 5,000,000 shares authorized; -0- and 777,654 issued and outstanding, respectively 0 0
Common stock $0.001 par value; 495,000,000 shares authorized; 50,048,273 and 45,566,363 shares issued and outstanding, respectively 50,049 45,567
Additional paid-in capital 81,087,973 80,939,618
Accumulated deficit (81,458,477) (80,603,069)
Total Cannabis Sativa, Inc. Stockholders' Equity (Deficit) (320,455) 382,116
Non-Controlling Interest 1,329,537 1,290,566
Total Stockholders' Equity 1,009,082 1,672,682
Total Liabilities and Stockholders' Equity $ 2,082,211 $ 2,570,791
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS    
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 5,000,000 5,000,000
Preferred Stock, Shares Issued 0 777,654
Preferred Stock, Shares Outstanding 0 777,654
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares Authorized 495,000,000 495,000,000
Common Stock, Shares, Issued 50,048,273 45,566,363
Common Stock, Shares, Outstanding 50,048,273 45,566,363
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED        
Revenues $ 323,197 $ 456,088 $ 668,565 $ 879,789
Cost of Revenues 120,608 170,541 226,009 329,230
Gross Profit 202,589 285,547 442,556 550,559
Operating Expenses        
Professional fees 108,757 89,502 161,898 211,408
Depreciation and amortization 37,990 42,354 75,979 84,707
Wages and salaries 209,690 184,150 324,793 370,911
Advertising 4,630 15,308 7,476 31,529
General and administrative 146,339 128,762 289,588 356,364
Total Operating Expenses 507,406 460,076 859,734 1,054,919
Loss from Operations (304,817) (174,529) (417,178) (504,360)
Other (Income) and Expenses        
Unrealized (gain) loss on investment 2,400 142,012 213,883 (104,642)
Loss on debt settlement (114) 0 10,527 0
Loss on sale of investment securities 0 0 155,735 0
Interest expense 9,233 1,995 19,114 19,171
Total Other (Income) Expenses, Net 11,519 144,007 399,259 (85,471)
Loss Before Income Taxes (316,336) (318,536) (816,437) (418,889)
Income Taxes 0 0 0 0
Net Loss for the Period (316,336) (318,536) (816,437) (418,889)
Income attributable to non-controlling interest - PrestoCorp 16,150 32,029 38,971 22,567
Net Loss for the Period Attributable To Cannabis Sativa, Inc. $ (332,486) $ (350,565) $ (855,408) $ (441,456)
Net Loss for the Period per Common Share: Basic & Diluted $ (0.01) $ (0.01) $ (0.02) $ (0.01)
Weighted Average Common Shares Outstanding: Basic & Diluted 48,169,783 31,394,764 46,926,618 31,370,814
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY - USD ($)
Total
Common Stock
Preferred Stock
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit)
Non Controlling Interest Prestocorp
Balance, shares at Dec. 31, 2021   30,746,865 777,654      
Balance, amount at Dec. 31, 2021 $ 1,044,900 $ 30,748 $ 778 $ 79,151,240 $ (79,475,968) $ 1,338,102
Net loss for period (100,353) $ 0 $ 0 0 (90,891) (9,462)
Balance, shares at Mar. 31, 2022   30,746,865 777,654      
Balance, amount at Mar. 31, 2022 944,547 $ 30,748 $ 778 79,151,240 (79,566,859) 1,328,640
Balance, shares at Dec. 31, 2021   30,746,865 777,654      
Balance, amount at Dec. 31, 2021 1,044,900 $ 30,748 $ 778 79,151,240 (79,475,968) 1,338,102
Net loss for period (418,889)          
Balance, shares at Jun. 30, 2022   44,750,479 815,884      
Balance, amount at Jun. 30, 2022 2,394,369 $ 44,751 $ 816 80,905,557 (79,917,424) 1,360,669
Balance, shares at Mar. 31, 2022   30,746,865 777,654      
Balance, amount at Mar. 31, 2022 944,547 $ 30,748 $ 778 79,151,240 (79,566,859) 1,328,640
Net loss for period (318,536) $ 0 $ 0 0 (350,565) 32,029
Conversion of preferred to common (1:1), shares   131,880 (131,880)      
Conversion of preferred to common (1:1), amount 0 $ 132 $ 132 0 0 0
Conversion of preferred to common (19:1), shares   5,476,237 (288,223)      
Conversion of preferred to common (19:1), amount 0 $ 5,476 $ (288) (5,188) 0 0
Shares issued for services, shares   1,306,242 458,333      
Shares issued for services, amount 350,507 $ 1,306 $ 458 348,743 0 0
Shares issued in consideration of notes and interest payable - related parties, shares   7,089,255        
Shares issued in consideration of notes and interest payable - related parties, amount 1,417,851 $ 7,089 $ 0 1,410,762 0 0
Balance, shares at Jun. 30, 2022   44,750,479 815,884      
Balance, amount at Jun. 30, 2022 2,394,369 $ 44,751 $ 816 80,905,557 (79,917,424) 1,360,669
Balance, shares at Dec. 31, 2022   45,566,363        
Balance, amount at Dec. 31, 2022 1,672,682 $ 45,567 0 80,939,618 (80,603,069) 1,290,566
Net loss for period (500,101) $ 0 0 0 (522,922) 22,821
Conversion of preferred to common (1:1), shares   320,513        
Conversion of preferred to common (1:1), amount 25,637 $ 321 0 25,316 0 0
Balance, shares at Mar. 31, 2023   45,886,876        
Balance, amount at Mar. 31, 2023 1,198,218 $ 45,888 0 80,964,934 (81,125,991) 1,313,387
Balance, shares at Dec. 31, 2022   45,566,363        
Balance, amount at Dec. 31, 2022 1,672,682 $ 45,567 0 80,939,618 (80,603,069) 1,290,566
Net loss for period (816,437)          
Balance, shares at Jun. 30, 2023   50,048,273        
Balance, amount at Jun. 30, 2023 1,009,082 $ 50,049 0 81,087,973 (81,458,477) 1,329,537
Balance, shares at Mar. 31, 2023   45,886,876        
Balance, amount at Mar. 31, 2023 1,198,218 $ 45,888 0 80,964,934 (81,125,991) 1,313,387
Net loss for period (316,336) $ 0 0 0 (332,486) 16,150
Conversion of preferred to common (1:1), shares   1,711,397        
Conversion of preferred to common (1:1), amount 39,000 $ 1,711 0 37,289 0 0
Shares issued for services, shares   2,450,000        
Shares issued for services, amount 88,200 $ 2,450 0 85,750 0 0
Balance, shares at Jun. 30, 2023   50,048,273        
Balance, amount at Jun. 30, 2023 $ 1,009,082 $ 50,049 $ 0 $ 81,087,973 $ (81,458,477) $ 1,329,537
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss for the period $ (816,437) $ (418,889)
Adjustments to reconcile net loss for the period to net cash used in operating activities:    
Unrealized loss (gain) on investments 213,883 (104,642)
Depreciation and amortization 75,979 84,707
Loss on debt settlement 10,527 0
Loss on sale of investment securities 155,735 0
Stock issued for services 88,200 350,507
Stock payable for services 196,527 0
Note payable issued for services 55,000 30,000
Write off of abandoned equipment 0 583
Changes in Assets and Liabilities:    
Accounts payable and accrued expenses (31,321) 1,424
Accrued interest - related parties 50 15,424
Net Cash Provided by (Used in) Operating Activities (51,857) (40,886)
Cash Flows from Investing Activities:    
Proceeds from sale of stock held for investment 9,040 0
Advances to related party (19,388) 0
Net Cash Used in Investing Activities (10,348) 0
Cash Flows from Financing Activities:    
Proceeds from related parties notes payable, net 22,884 41,340
Net Cash Provided by Financing Activities 22,884 41,340
NET CHANGE IN CASH (39,321) 454
CASH AT BEGINNING OF PERIOD 97,445 194,060
CASH AT END OF PERIOD 58,124 194,514
Noncash investing and financing activities    
Shares issued in consideration of notes and interest payable - related parties 30,000 1,417,851
Shares issued in consideration of convertible notes payable 39,000  
Recognition of operating lease liability and right of use asset $ 0 $ 56,595
v3.23.2
Organization and Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Organization and Summary of Significant Accounting Policies  
Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

 

Nature of Business:

 

Cannabis Sativa, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including:

 

 

·

PrestoCorp, Inc. (“PrestoCorp”)

 

·

Wild Earth Naturals, Inc. (“Wild Earth”)

 

·

Kubby Patent and Licenses Limited Liability Company (“KPAL”)

 

·

Hi Brands, International, Inc. (“Hi Brands”)

 

·

Eden Holdings LLC (“Eden”).

 

PrestoCorp is a 51% owned subsidiary and until April 22, 2021, GKMP and iBud were 51% and 50.1% owned subsidiaries. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At December 31, 2022 and 2021, PrestoCorp is the sole operating subsidiary. Until sale of the Company’s interest in April 2021, GKMP and iBud tender were operating subsidiaries although iBud was not generating any revenue.

 

Our primary operations for the years ended December 31, 2022 through June 30, 2023 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.

 

Basis of Presentation

 

Operating results for the three and six months ended June 30, 2023 may not be indicative of the results expected for the full year ending December 31, 2023. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2022, as filed with the United States Securities and Exchange Commission on April 20, 2023.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023, and its results of operations, cash flows, and changes in stockholders’ equity for the three and six months ended June 30, 2023. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.

 

Principles of Consolidation:

 

The consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.

Going Concern:

 

The Company has an accumulated deficit of $81,458,477 at June 30, 2023, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

 

Use of Estimates:

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

 

 Net Loss per Share:

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the six months ended June 30, 2023 and 2022, the Company had 50,000 and 175,000 outstanding warrants, respectively, and -0- and 777,654 shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted. The number of shares that can be converted per the convertible note agreement can be converted after December 31, 2022 thus are dilutive as of June 30, 2023.

 

Recent Accounting Pronouncement:

 

Accounting Standards Updates Adopted

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

v3.23.2
Intangibles and Goodwill
6 Months Ended
Jun. 30, 2023
Intangibles and Goodwill  
Intangibles and Goodwill

2. Intangibles and Goodwill

 

The Company considers all intangibles to be definite-lived assets with lives of 5 to 10 years. Intangibles consisted of the following at June 30, 2023   and December 31, 2022:

 

 

 

June 30,

2023

 

 

December 31,

2022

 

CBDS.com website (Cannabis Sativa)

 

$13,999

 

 

$13,999

 

Intellectual Property Rights (PrestoCorp)

 

 

240,000

 

 

 

240,000

 

Patents and Trademarks (KPAL)

 

 

1,281,411

 

 

 

1,281,411

 

Total Intangibles

 

 

1,535,410

 

 

 

1,535,410

 

Less: Accumulated Amortization

 

 

(1,452,309 )

 

 

(1,376,467 )

Net Intangible Assets

 

$83,101

 

 

$158,943

 

 

Amortization expense for the three and six months ended June 30, 2023 and 2022 was $37,921 (2022: $42,285) and $75,842 (2022: $84,570), respectively.

 

Amortization of intangibles through 2027 is: 

 

July 1, 2023 to June 30, 2024

 

$78,432

 

July 1, 2024 to June 30, 2025

 

 

932

 

July 1, 2025 to June 30, 2026

 

 

932

 

July 1, 2026 to June 30, 2027

 

 

932

 

July 1, 2027 to June 30, 2028

 

 

932

 

July 1, 2028 to June 30, 2029

 

 

941

 

 

Goodwill in the amount of $3,010,202 was recorded as part of the acquisition of PrestoCorp that occurred on August 1, 2017. Cumulative impairment of the PrestoCorp goodwill totals $1,173,000 as of June 30, 2023 and December 31, 2022. The balance of goodwill at June 30, 2023 and December 31, 2022 was $1,837,202.

v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions  
Related Party Transactions

3. Related Party Transactions

 

In addition to items disclosed in Note 6, the Company had additional related party transactions during the six months ended June 30, 2023 and 2022.

 

Historically, the Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company’s outstanding shares.

 

During the six months ended June 30, 2023, David Tobias, the Company’s chief executive officer and director, loaned $22,721 to the Company for notes payable bearing interest at the rate of 5% per annum due on December 31, 2023. 

 

During the six months ended June 30, 2023, the Company and Cathy Carroll, director, entered into a note payable for $30,000 for compensation due her for services. Ms. Carroll’s note bears interest at 8% per annum and is due December 31, 2024. The note payable totaled $55,000 at December 31, 2022.

 

During the years ended December 31, 2022 and 2021, the Company recorded interest expense related to notes payable to related parties at the rates between 5% and 8% per annum in the amounts of $16,374 and $66,872, respectively.

 

The following tables reflect the related party note payable balances. 

 

 

 

Related party notes

 

 

Accrued interest

 

 

Total

 

 

 

June 30, 2023

 

David Tobias, CEO & Director

 

$55,421

 

 

$12,482

 

 

$67,903

 

New Compendium, greater than 10% Shareholder

 

 

-

 

 

 

1,906

 

 

 

1,906

 

Cathy Carroll, Director

 

 

85,000

 

 

 

986

 

 

 

85,986

 

Other Affiliates

 

 

4,000

 

 

 

1,100

 

 

 

5,100

 

Totals

 

$144,421

 

 

$16,474

 

 

$160,895

 

 

 

 

Related party notes

 

 

Accrued interest

 

 

Total

 

 

 

December 31, 2022

 

David Tobias, CEO & Director

 

$32,700

 

 

$12,482

 

 

$45,182

 

New Compendium, greater than 10% Shareholder

 

––

 

 

 

1,906

 

 

 

1,906

 

Cathy Carroll, Director

 

 

55,000

 

 

 

986

 

 

 

55,986

 

Other Affiliates

 

 

4,000

 

 

 

1,000

 

 

 

5,000

 

Totals

 

$91,700

 

 

$16,374

 

 

$108,074

 

 

During the three and six months ended June 30, 2023 and 2022, the Company incurred approximately $-0- (2022: $12,500) and $-0- (2022: $26,389), respectively, for consulting services from a nephew of the Company’s president. The services were accrued at June 30, 2022 and paid in common stock. These amounts are included in the statements of operations in general and administrative expenses.

At June 30, 2023 and December 31, 2022, the Company has a balance due from MJ Harvest, Inc., with whom the Company plans to merge, of $75,054 and $55,666 (see Note 8). The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to MJ Harvest, Inc. to cover operating expenses.

 

At June 30, 2023 and December 31, 2022 the Company had stock payable in the amount $542,421 and $345,893 due to related parties; directors and contract officers.

v3.23.2
Investments
6 Months Ended
Jun. 30, 2023
Investments  
Investments

4. Investments

 

At June 30, 2023 and December 31, 2022, the Company owns -0- and 8,238,769 shares respectively, of common stock of Medical Cannabis Payment Solutions (ticker: REFG). At June 30, 2023 and December 31, 2022, the fair value of the investment in REFG was $-0- and $12,358, respectively. The Company sold all of its position in REFG during the six months ended June 30, 2023 and recognized a loss on the sale of investment securities in the amount of $155,735. 

 

In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG.

 

The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at June 30, 2023 and December 31, 2022 was $1,200 and $367,500 resulting in a gain (loss) of ($2,400) (2022: $114,000) and ($366,300) (2022: ($117,000)) for the change in fair value during the three and six months ended June 30, 2023 and 2022, respectively.

v3.23.2
Convertible Notes Payable
6 Months Ended
Jun. 30, 2023
Convertible Notes Payable  
Convertible Notes Payable

5. Convertible Notes Payable

 

On August 25, 2022 and November 7, 2022, the Company entered into an agreement with 1800 Diagonal Lending, LLC (“Diagonal”) whereby the Company issued convertible notes to Diagonal with principal amounts of $104,250 and $64,250, respectively. The notes bear interest at 10% and have terms of one year when payment of principal and interest is due. After 180 days, the notes are convertible into shares of the Company’s common stock the number of which determined by dividing the principal balance outstanding by 65% of the lowest trading price of the Company’s stock during the five previous trading days before the date of the conversion.  During the six months ended June 30, 2023, Diagonal converted $54,000 of their note payable from August into 2,031,910 shares of common stock.  As of June 30, 2023 amounts due to Diagonal total $50,250 and $64,250, respectively.

 

On January 1, 2023, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $72,262.  As stated in the January 1, 2023 agreement Ms. Merrill’s contract compensation will also be added to the note for her services through June 30, 2023 in the amount of $25,000. Total note payable at June 30, 2023 is $97,262.  The note bears interest at 8% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 20% discount.  Both methods are calculated using the lowest 3 closing prices during the 15 trading days preceding the first day of the next calendar quarter.

At June 30, 2023 and December 31, 2022, accrued interest payable and interest expense on these notes was $16,362 and $4,546. Accrued interest payable is included in accounts payable and accrued expenses on the consolidated balance sheet.

v3.23.2
Stockholders Equity
6 Months Ended
Jun. 30, 2023
Stockholders Equity  
Stockholders' Equity

6. Stockholders’ Equity

 

Change in Authorized Shares

 

The Company increased the number of authorized common shares the Company is authorized to issue to 495,000,000 on August 8, 2022. This change in capital structure was approved without a meeting by the consent of the shareholders holding a majority of the common stock outstanding and Articles of Amendment were filed with the State of Nevada.

 

Securities Issuances

 

During the six months ended June 30, 2023, 2,031,910 shares of common stock were issued to convert $54,000 of a note payable to a non-related party.  See Note 5.

 

During the six months ended June 30, 2023, 2,450,000 shares of common stock were issued to pay bonuses in the amount of  $88,200. 

 

Stock payable at June 30, 2023 consists of 1,219,513 preferred shares and 838,415 common shares owed to members of the board of directors for directors’ fees and contract services. These shares were valued at $84,375 based on the fair value of the Company’s common stock at the date of board authorization. Subsequent to year end, no issuances of the shares have been made.

 

Stock payable at June 30, 2023 and December 31, 2022 consists of 5,025,814 and 1,306,302 preferred shares and 1,934,530 and 1,469,590 common shares, respectively, owed to members of the board of directors for directors’ fees and contract services. These shares were valued at $325,000 and  $212,500, respectively, based on the fair value of the Company’s common stock at the date of board authorization. An additional 5,874,988 and 2,393,873 common shares were owed to various non-related vendors at June 30, 2023 and December 31, 2022 valued at $217,421 and $205,656, respectively, based on the fair value of the Company’s common stock at the date of board authorization. Subsequent to year end, no issuances of the shares have been made.

 

Stock Compensation Plans

 

2020 Stock Plan

 

On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021. At June 30, 2023, 44,425 shares were available for future issuance.

Warrants

 

At June 30, 2023 and December 31, 2022, the Company has outstanding warrants to purchase 50,000 shares of the Company’s common stock. As of June 30, 2023, the warrants have an exercise price of $2.00 and expire in July and August 2023. During the six months ended June 30, 2023 and 2022, warrants activity consisted of the following: warrants issued – none (2022: none), warrants exercised – none (2022: none), warrants expired – none (2022: none).

v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and contingencies (Notes 6 and 8)  
Commitments and Contingencies

7. Commitments and Contingencies

 

Leases.

 

PrestoCorp leased office space through WeWork in New York on a month-to-month basis which ended in April 2022. On April 12, 2022, PrestoCorp signed a new lease in New York with Spaces for a two-year term at $2,590 per month expiring in April 2024. Upon signing the lease with Spaces, the Company recognized a lease liability and a right of use asset of $56,595 using a discount rate of 10%. The future lease payments under the new lease are as follows:

 

From July 1, 2023 to June 30, 2024

 

$25,900

 

Less imputed interest

 

 

(942 )

Net lease liability

 

 

24,958

 

Current Portion

 

 

(24,958 )

Long-term portion

 

$

-0-

 

 

Rent expense for the three and six months ended June 30, 2023 and 2022 was $9,163 (2022: $2,602) and $17,579 (2022: $21,325), respectively.

 

Litigation.

 

In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of June 30, 2023, no claims are outstanding.

v3.23.2
Proposed Merger with MJ Harvest Inc
6 Months Ended
Jun. 30, 2023
Proposed Merger with MJ Harvest Inc  
Proposed Merger with MJ Harvest, Inc.

8. Proposed Merger with MJ Harvest, Inc.

 

On August 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with MJ Harvest, Inc. (“MJHI”). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger. The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the second quarter of calendar year 2023. The terms of the Merger Agreement are summarized below:

 

 

·

The name of the surviving company in the Merger will be Cannabis Sativa, Inc.

 

·

Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock.

 

·

The Merger is subject to majority approval of the shareholders of both MJHI and CBDS.

 

·

The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares.

 

·

The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Randy Lanier, Clinton Pyatt, and David Tobias.

 

·

The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer, Clinton Pyatt - Chief Operating Officer.

 

·

The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature.

 

·

No brokerage fees are payable in connection with the Merger.

 

·

If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated.

 

·

All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs.

v3.23.2
Subsequent Event
6 Months Ended
Jun. 30, 2023
Subsequent Event  
Subsequent Event

9.  Subsequent Event

 

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

v3.23.2
Organization and Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Organization and Summary of Significant Accounting Policies  
Nature of Business

Cannabis Sativa, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including:

 

 

·

PrestoCorp, Inc. (“PrestoCorp”)

 

·

Wild Earth Naturals, Inc. (“Wild Earth”)

 

·

Kubby Patent and Licenses Limited Liability Company (“KPAL”)

 

·

Hi Brands, International, Inc. (“Hi Brands”)

 

·

Eden Holdings LLC (“Eden”).

 

PrestoCorp is a 51% owned subsidiary and until April 22, 2021, GKMP and iBud were 51% and 50.1% owned subsidiaries. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At December 31, 2022 and 2021, PrestoCorp is the sole operating subsidiary. Until sale of the Company’s interest in April 2021, GKMP and iBud tender were operating subsidiaries although iBud was not generating any revenue.

 

Our primary operations for the years ended December 31, 2022 through June 30, 2023 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.

Basis of Presentation

Operating results for the three and six months ended June 30, 2023 may not be indicative of the results expected for the full year ending December 31, 2023. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2022, as filed with the United States Securities and Exchange Commission on April 20, 2023.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023, and its results of operations, cash flows, and changes in stockholders’ equity for the three and six months ended June 30, 2023. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.

Principles of Consolidation

The consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.

Going Concern

The Company has an accumulated deficit of $81,458,477 at June 30, 2023, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

Net Loss per Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the six months ended June 30, 2023 and 2022, the Company had 50,000 and 175,000 outstanding warrants, respectively, and -0- and 777,654 shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted. The number of shares that can be converted per the convertible note agreement can be converted after December 31, 2022 thus are dilutive as of June 30, 2023.

Recent Accounting Pronouncement

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

v3.23.2
Intangibles and Goodwill (Tables)
6 Months Ended
Jun. 30, 2023
Intangibles and Goodwill  
Schedule of Intangible Assets

 

 

June 30,

2023

 

 

December 31,

2022

 

CBDS.com website (Cannabis Sativa)

 

$13,999

 

 

$13,999

 

Intellectual Property Rights (PrestoCorp)

 

 

240,000

 

 

 

240,000

 

Patents and Trademarks (KPAL)

 

 

1,281,411

 

 

 

1,281,411

 

Total Intangibles

 

 

1,535,410

 

 

 

1,535,410

 

Less: Accumulated Amortization

 

 

(1,452,309 )

 

 

(1,376,467 )

Net Intangible Assets

 

$83,101

 

 

$158,943

 

Schedule of amortization

July 1, 2023 to June 30, 2024

 

$78,432

 

July 1, 2024 to June 30, 2025

 

 

932

 

July 1, 2025 to June 30, 2026

 

 

932

 

July 1, 2026 to June 30, 2027

 

 

932

 

July 1, 2027 to June 30, 2028

 

 

932

 

July 1, 2028 to June 30, 2029

 

 

941

 

v3.23.2
Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2023
Related Party Transactions  
Schedule of related party advance and note payable

 

 

Related party notes

 

 

Accrued interest

 

 

Total

 

 

 

June 30, 2023

 

David Tobias, CEO & Director

 

$55,421

 

 

$12,482

 

 

$67,903

 

New Compendium, greater than 10% Shareholder

 

 

-

 

 

 

1,906

 

 

 

1,906

 

Cathy Carroll, Director

 

 

85,000

 

 

 

986

 

 

 

85,986

 

Other Affiliates

 

 

4,000

 

 

 

1,100

 

 

 

5,100

 

Totals

 

$144,421

 

 

$16,474

 

 

$160,895

 

 

 

 

Related party notes

 

 

Accrued interest

 

 

Total

 

 

 

December 31, 2022

 

David Tobias, CEO & Director

 

$32,700

 

 

$12,482

 

 

$45,182

 

New Compendium, greater than 10% Shareholder

 

––

 

 

 

1,906

 

 

 

1,906

 

Cathy Carroll, Director

 

 

55,000

 

 

 

986

 

 

 

55,986

 

Other Affiliates

 

 

4,000

 

 

 

1,000

 

 

 

5,000

 

Totals

 

$91,700

 

 

$16,374

 

 

$108,074

 

v3.23.2
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2023
Commitments and contingencies (Notes 6 and 8)  
Schedule of future lease payments

From July 1, 2023 to June 30, 2024

 

$25,900

 

Less imputed interest

 

 

(942 )

Net lease liability

 

 

24,958

 

Current Portion

 

 

(24,958 )

Long-term portion

 

$

-0-

 

v3.23.2
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Accumulated deficit $ (81,458,477)   $ (80,603,069)
Warrant      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 50,000 175,000  
Convertible Series A Preferred Stock [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 777,654  
Preferred Stock [Member]      
Equity Method Investment, Ownership Percentage 51.00%    
Cannabis Sativa [Member] | Internet Domain Names [Member]      
Equity Method Investment, Ownership Percentage 50.10%    
v3.23.2
Intangibles and Goodwill (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Total Intangibles $ 1,535,410 $ 1,535,410
Less: Accumulated Amortization (1,452,309) (1,376,467)
Net Intangible Assets 83,101 158,943
Intellectual Property [Member] | Prestocorp [Member]    
Total Intangibles 240,000 240,000
Cannabis Sativa [Member] | Internet Domain Names [Member]    
Total Intangibles 13,999 13,999
K P A L [Member] | Patents And Trademarks [Member]    
Total Intangibles $ 1,281,411 $ 1,281,411
v3.23.2
Intangibles and Goodwill (Details 1)
Jun. 30, 2023
USD ($)
Intangibles and Goodwill  
April 1, 2023 to June 30, 2024 $ 78,432
April 1, 2024 to June 30, 2025 932
April 1, 2025 to June 30, 2026 932
April 1, 2026 to June 30, 2027 932
April 1, 2027 to June 30, 2028 932
April 1, 2028 to June 30, 2029 $ 941
v3.23.2
Intangibles and Goodwill (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Amortization of Intangible Assets $ 37,921 $ 42,285 $ 75,842 $ 84,570    
Goodwill $ 1,837,202   1,837,202   $ 1,837,202 $ 1,837,202
Prestocorp [Member] | August 1, 2017 [Member]            
Impairment of goodwill     $ 3,010,202      
Cumulative impairment of goodwill         $ 1,173,000 $ 1,173,000
Minimum [Member]            
Finite-Lived Intangible Asset, Useful Life     5 years      
Maximum [Member]            
Finite-Lived Intangible Asset, Useful Life     10 years      
v3.23.2
Related Party Transactions (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Notes Payable to Related Parties $ 144,421 $ 91,700
Accrued interest - related parties 16,474 16,374
Total 160,895 108,074
David Tobias, CEO &amp    
Notes Payable to Related Parties 55,421 32,700
Accrued interest - related parties 12,482 12,482
Total 67,903 45,182
New Compendium Affiliate [Member]    
Notes Payable to Related Parties 0  
Accrued interest - related parties 1,906 1,906
Total 1,906 1,906
Cathy Carroll, Director    
Notes Payable to Related Parties 85,000 55,000
Accrued interest - related parties 986 986
Total 85,986 55,986
Other Affiliates [Member]    
Notes Payable to Related Parties 4,000 4,000
Accrued interest - related parties 1,100 1,000
Total $ 5,100 $ 5,000
v3.23.2
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Interest Expense         $ 16,374 $ 66,872
Advances to related party $ 75,054   $ 75,054   55,666  
Cathy Carroll, Director            
Compensation due for services     $ 30,000      
Interest rate     8.00%      
Note Payable 55,000   $ 55,000      
Directors And Contract Officers [Member]            
Stock payable due to related parties     542,421   345,893  
David Tobias, Director            
Advances to related party 75,054   $ 75,054   $ 55,666  
Interest rate     5.00%      
Note Payable 22,721   $ 22,721      
Consultant [Member]            
Other General and Administrative Expense $ 0 $ 12,500 $ 0 $ 26,389    
Minimum [Member]            
Debt Instrument, Interest Rate, Stated Percentage 5.00%   5.00%      
Maximum [Member]            
Debt Instrument, Interest Rate, Stated Percentage 8.00%   8.00%      
v3.23.2
Investments (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Stock Issued During Period, Shares, Purchase of Assets     0   8,238,769  
Unrealized (gain) loss on investment $ 2,400 $ 142,012 $ 213,883 $ (104,642)    
C B D G [Member]            
Share price         $ 0.20  
Fair value of investment 1,200   1,200   $ 367,500  
Proceeds from sales of equity         $ 600,000  
Percentage of voting share held by director         15.00%  
Unrealized (gain) loss on investment (2,400) $ 114,000 (366,300) $ (117,000)    
C B D G [Member] | Preferred Stock One [Member]            
Stock Issued During Period, Shares, Purchase of Assets           1,500,000
C B D G [Member] | Common Stock One [Member]            
Stock Issued During Period, Shares, Purchase of Assets           1,500,000
R E F G [Member]            
Fair value of investment $ 0   0   $ 12,358  
Loss on the sale of investment securities     155,735      
Gain on the change in fair value     $ 15,654      
v3.23.2
Convertible Note Payable (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jan. 02, 2023
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Jan. 01, 2023
Dec. 31, 2022
Nov. 07, 2022
Aug. 25, 2022
Common stock shares issued     2,450,000          
Accrued interest payable and interest expense     $ 16,362     $ 4,546    
Notes Payable   $ 6,340 $ 22,884 $ 41,340        
Diagonal Lending, LLC [Member]                
Principal Amount             $ 64,250 $ 104,250
Principal balance outstanding lowest trading price, percentage               65.00%
Common stock shares issued     2,031,910          
Notes payable due     $ 50,250     $ 64,250    
Convertible notes payable     54,000          
Carolyn Merrill [Member]                
Principal Amount         $ 72,262      
Interest rate 8.00%              
Compensation         $ 25,000      
Agreement payment description If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 20% discount              
Notes Payable     $ 97,262          
v3.23.2
Stockholders Equity (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Common Stock, Shares Authorized 495,000,000   495,000,000
Stock payable, value $ 325,000   $ 212,500
Additional common shares owed to various non-related vendors, Shares 5,874,988   2,393,873
Additional common shares owed to various non-related vendors, Amount $ 217,421   $ 205,656
Common stock shares issued 2,450,000    
Stock issued for services $ 88,200 $ 350,507  
Board of Directors [Member]      
Stock payable, value $ 84,375    
Warrants      
Outstanding warrants 50,000   50,000
Exercise price     $ 2.00
2021 Stock Plan      
Shares available for future issuance 44,425    
2020 Stock Plan      
Shares available for future issuance 1,000,000    
Increased number of shares available for future issuance 2,000,000    
Preferred Stock [Member]      
Stock payable 5,025,814   1,306,302
Preferred Stock [Member] | Board of Directors [Member]      
Stock payable 1,219,513    
Common Stock [Member]      
Stock payable 1,934,530   1,469,590
Common Stock [Member] | Board of Directors [Member]      
Stock payable 838,415    
Non Related Party [Member]      
Common stock shares issued 2,031,910    
Convertible notes payable $ 54,000    
v3.23.2
Commitments and Contingencies (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Commitments and contingencies (Notes 6 and 8)    
From July 1, 2023 to June 30, 2024 $ 25,900  
Less imputed interest 942  
Net lease liability 24,958  
Current Portion 24,958 $ 28,736
Long-term portion $ 0 $ 10,232
v3.23.2
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Recognition of operating lease liability and right of use asset     $ 56,595  
Discount rate 10.00%   10.00%  
Prestocorp [Member] | New York office Facilities        
Description of lease     two-year term at $2,590 per month expiring in April 2024  
Rent expense $ 9,163 $ 2,602 $ 17,579 $ 21,325

1 Year Cannabis Sativa (QB) Chart

1 Year Cannabis Sativa (QB) Chart

1 Month Cannabis Sativa (QB) Chart

1 Month Cannabis Sativa (QB) Chart